Clicky

Author name: systems

Considerations for Treating Patients With Depression and COVID-19

(Part 4 of a 4-part series) In this video, Jonathan E. Alpert, MD, PhD, of Albert Einstein College of Medicine and Montefiore Medical Center, New York City, New York, discusses special considerations for treating depression when patients have COVID‑19. Dr. Alpert recently presented “Treating Depression with Other Medical Comorbidity” at the Nevada Psychiatric Association’s 26th National Psychopharmacology Update. Part 1: Dr. […]

Considerations for Treating Patients With Depression and COVID-19 Read More »

Profound loss of pleasure related to early-onset dementia

IMAGE: Neuroimaging findings show grey matter intensity decreases related to anhedonia, apathy and depression. Anhedonia in FTD was related to degeneration of the regions circled in green, which are ‘hedonic hotspots’… view more  Credit: University of Sydney KEY POINTS: – Loss of pleasure has been revealed as a key feature in early-onset dementia (FTD), in contrast

Profound loss of pleasure related to early-onset dementia Read More »

How a radical interpretation of the Great Depression became the orthodoxy behind solving the COVID crisis

At the start of the COVID-19 pandemic in March 2020, US Federal Reserve System governor Jerome Powell made an extraordinary declaration: “We’re not going to run out of ammunition.” The central bank stood ready to take any action necessary to stem the mounting economic crisis. Three months later, the Fed injected nearly US$3 trillion dollars

How a radical interpretation of the Great Depression became the orthodoxy behind solving the COVID crisis Read More »

Toad venom to treat depression? RA Capital wagers $125M on latest psychedelic biotech – Endpoints News

Can an in­haled ver­sion of the psy­che­del­ic known as ‘toad ven­om’ be used to treat tough-to-crack de­pres­sion? For GH Re­search, that’s the $125 mil­lion ques­tion. The Dublin-based biotech an­nounced Mon­day it closed a Se­ries B round to help ad­vance its lead pro­gram, an in­halant called GH001, for psy­chi­atric and neu­ro­log­i­cal dis­or­ders. GH is be­gin­ning with

Toad venom to treat depression? RA Capital wagers $125M on latest psychedelic biotech – Endpoints News Read More »

[Full text] Association Between Depression and Hospital Length of Stay

Introduction Cardiovascular diseases (CVDs) remain the main cause of death worldwide,1 and over two-thirds of these deaths occur in developing countries.2 One of the most common CVDs is Coronary Heart Disease (CHD),3 and its treatments and controlling factors affecting outcomes are of fundamental significance for health systems. Coronary Artery Bypass Graft Surgery (CABG) is the

[Full text] Association Between Depression and Hospital Length of Stay Read More »

Adapting Depression Treatment in Patients With Comorbid Medical Conditions

(Part 3 of a 4-part series) In this video, Jonathan E. Alpert, MD, PhD, of Albert Einstein College of Medicine and Montefiore Medical Center, New York City, New York, discusses strategies for adapting depression treatment in patients who also have medical comorbidities. Dr. Alpert recently presented “Treating Depression with Other Medical Comorbidity” at the Nevada Psychiatric

Adapting Depression Treatment in Patients With Comorbid Medical Conditions Read More »

Association Between Depression and Hospital Length of Stay

Mohannad Eid AbuRuz, Aaliyah Momani, AbedAlmajeed Shajrawi Clinical Nursing Department, Faculty of Nursing, Applied Science Private University, Amman, Jordan Correspondence: Mohannad Eid AbuRuzClinical Nursing Department, Faculty of Nursing, Applied Science Private University, PO Box 142, Shafa Badran, Amman, 11934, JordanTel +962 790262408Fax +962 65232899Email [email protected] Purpose: Depressive symptoms can negatively influence patient outcomes after coronary

Association Between Depression and Hospital Length of Stay Read More »